Condition: Paroxysmal Atrial Fibrillation (PAF) · Sponsor: Abbott Medical Devices
The purpose of the trial is to find out if the Grid X Mapping Catheter and EnSite X EP System with EnSite X Software v3.1.1, the devices that are being studied, are safe and effective in treating Chinese patients who have atrial fibrillation. Participants will receive a procedure called catheter mapping and ablation to treat their abnormal heart rhythms and are required to complete 4 follow-up visits at 7 days, 3 months, 6 months and 12 months after the procedure for checkups and tests.
This description comes directly from the study's public registry record.
Rio Zhan · +86-21-2320 4181 · wanlei.zhan@abbott.com
Always discuss trial participation with your own doctor first.
| Qilu Hospital of Shandong University | Jinan, Shandong, China | Recruiting |
| West China Hospital of Sichuan University | Chengdu, Sichuan, China | Recruiting |
| Sir Run Run Shaw Hospital Zhejiang University School of Medicine | Hangzhou, Zhejiang, China | Recruiting |
| The First Affiliated Hospital of Ningbo University | Ningbo, Zhejiang, China | Recruiting |
| Beijing Anzhen Hospital, Capital Medical University | Beijing, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07421076